|
|
|
|
| LEADER |
03866nma a2200805 u 4500 |
| 001 |
EB001992812 |
| 003 |
EBX01000000000000001155714 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a books978-3-03943-624-8
|
| 020 |
|
|
|a 9783039436248
|
| 020 |
|
|
|a 9783039436231
|
| 100 |
1 |
|
|a Saiz, Juan Carlos
|
| 245 |
0 |
0 |
|a Vaccines against RNA Viruses
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (166 p.)
|
| 653 |
|
|
|a peptide mimic of discontinuous epitope
|
| 653 |
|
|
|a vaccines
|
| 653 |
|
|
|a PRRSV Mosaic T-cell DNA vaccine VACV
|
| 653 |
|
|
|a amount
|
| 653 |
|
|
|a animal models
|
| 653 |
|
|
|a N gene
|
| 653 |
|
|
|a flavivirus
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a herd immunity
|
| 653 |
|
|
|a intestine epithelial cells
|
| 653 |
|
|
|a pig
|
| 653 |
|
|
|a hepatitis C virus
|
| 653 |
|
|
|a cellular response
|
| 653 |
|
|
|a Medicine / bicssc
|
| 653 |
|
|
|a processivity factor
|
| 653 |
|
|
|a immunogenicity
|
| 653 |
|
|
|a FMDV
|
| 653 |
|
|
|a immune responses
|
| 653 |
|
|
|a epitopes of broadly neutralizing HIV-1 antibodies
|
| 653 |
|
|
|a VHSV
|
| 653 |
|
|
|a polyepitope B- and T-cell HIV-1 immunogen
|
| 653 |
|
|
|a heterologous virus challenge
|
| 653 |
|
|
|a artificial protein
|
| 653 |
|
|
|a RNA interference
|
| 653 |
|
|
|a transcriptome profiling
|
| 653 |
|
|
|a birds
|
| 653 |
|
|
|a peptide vaccine
|
| 653 |
|
|
|a modified vaccinia Ankara (MVA)
|
| 653 |
|
|
|a non-virion (NV)
|
| 653 |
|
|
|a Rift Valley fever virus (RVFV)
|
| 653 |
|
|
|a single dose
|
| 653 |
|
|
|a neutralizing antibodies
|
| 653 |
|
|
|a Gn Gc glycoproteins
|
| 653 |
|
|
|a PRRS
|
| 653 |
|
|
|a West Nile virus
|
| 653 |
|
|
|a rotavirus nanoparticle vaccine
|
| 653 |
|
|
|a passive serum:virus transfer
|
| 653 |
|
|
|a rainbow trout
|
| 653 |
|
|
|a cross protection
|
| 653 |
|
|
|a neutralising antibodies
|
| 653 |
|
|
|a gnotobiotic pigs
|
| 653 |
|
|
|a porcine epidemic diarrhea virus
|
| 653 |
|
|
|a immune pathways
|
| 700 |
1 |
|
|a Saiz, Juan Carlos
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-03943-624-8
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/69449
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/3253
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches, from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts.
|